Article Versions Notes

Yang C, Khwaja R, Tang P, Nixon N, King K, Lupichuk S. A Review of Trastuzumab Biosimilars in Early Breast Cancer and Real World Outcomes of Neoadjuvant MYL-1401O versus Reference Trastuzumab. Current Oncology. 2022; 29(6):4224-4234. https://doi.org/10.3390/curroncol29060337

Yang, Charlie, Raida Khwaja, Patricia Tang, Nancy Nixon, Karen King, and Sasha Lupichuk. 2022. "A Review of Trastuzumab Biosimilars in Early Breast Cancer and Real World Outcomes of Neoadjuvant MYL-1401O versus Reference Trastuzumab" Current Oncology 29, no. 6: 4224-4234. https://doi.org/10.3390/curroncol29060337

Yang, C., Khwaja, R., Tang, P., Nixon, N., King, K., & Lupichuk, S. (2022). A Review of Trastuzumab Biosimilars in Early Breast Cancer and Real World Outcomes of Neoadjuvant MYL-1401O versus Reference Trastuzumab. Current Oncology, 29(6), 4224-4234. https://doi.org/10.3390/curroncol29060337